- Research works
- 28 ▲ 24% vs 2013–17
- Citations
- 414 14.9 per fractional work
- Top-10% rate
- 18.1% record average 16.5%
- Open access
- 31% world 28%
Not ranked overall: CSPC Pharmaceutical Group is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Immunology and Microbiology, 4.8×. Every wedge is a field page.
Which keywords describe research at CSPC Pharmaceutical Group?
By fractional works in all years, weighted toward what it does more of than the world: Chemotherapy, Epidemiology, Breast Cancer, Nanoparticles, Drug Resistance, Cancer, Monoclonal Antibody and Cyclodextrins.
- Trastuzumab
- HER2
- Antibiotic Resistance
- Cyclodextrins
- Monoclonal Antibody
- Inflammation
- Nanoparticles
- Chemotherapy
- Epidemiology
- Cancer
- Breast Cancer
- Drug Resistance
- Antioxidant
- Solid Dispersions
- Antimicrobial Stewardship
- Prognostic Factors
Size is fractional works in all years in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 16 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 16 words, with their numbers
- Epidemiology3▲ 2.7×14 topics
- Chemotherapy2▲ 12×10 topics
- Cancer2▲ 5.0×13 topics
- Nanoparticles2▲ 5.2×8 topics
- Breast Cancer2▲ 23×4 topics
- Inflammation2▲ 2.8×10 topics
- Drug Resistance2▲ 18×3 topics
- Monoclonal Antibody1▲ 70×2 topics
- Antioxidant1▲ 5.6×5 topics
- Cyclodextrins1▲ 178×1 topic
- Solid Dispersions1▲ 178×1 topic
- Antibiotic Resistance1▲ 8.9×1 topic
- Antimicrobial Stewardship1▲ 122×1 topic
- HER21▲ 121×1 topic
- Prognostic Factors1▲ 8.0×7 topics
- Trastuzumab1▲ 86×1 topic
Which research topics does CSPC Pharmaceutical Group publish most on?
By volume in 2022–2025: HER2/EGFR in Cancer Research, Monoclonal and Polyclonal Antibodies Research, Chronic Lymphocytic Leukemia Research and Glioma Diagnosis and Treatment.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 HER2/EGFR in Cancer Research Oncology 1 works
- 2 Monoclonal and Polyclonal Antibodies Research Radiology, Nuclear Medicine and Imaging 0 works
- 3 Chronic Lymphocytic Leukemia Research Genetics 0 works
- 4 Glioma Diagnosis and Treatment Genetics 0 works
- 5 Estrogen and related hormone effects Genetics 0 works
- 6 Advanced Breast Cancer Therapies Pulmonary and Respiratory Medicine 0 works
- 7 Cell Adhesion Molecules Research Immunology and Allergy 0 works
- 8 HIV/AIDS drug development and treatment Infectious Diseases 0 works
- 9 Cancer, Hypoxia, and Metabolism Cancer Research 0 works
- 10 SARS-CoV-2 and COVID-19 Research Infectious Diseases 0 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has CSPC Pharmaceutical Group's research output changed?
Output in 2018–2022 was 24% higher than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Shijiazhuang
- Hebei Medical University
- Hebei Normal University
- Hebei University of Science and Technology
- Shijiazhuang Tiedao University
- Ordnance Engineering College
- Shijiazhuang University
- Second Hospital of Hebei Medical University
- Hebei GEO University
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.